Tafamidis
Abstract:
In November 2011, tafamidis (Vyndaqel; Pfizer), a small molecule that inhibits the dissociation of transthyretin tetramers, was granted marketing authorization by the European Commission for the treatment of transthyretin amyloidosis in adult patients with stage 1 symptomatic polyneuropathy to delay peripheral neurological impairment.
More Related Videos
08:38Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
Published on: November 8, 2015
11:44Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B
Published on: January 19, 2022
Related Concept Videos
Desensitization and Tachyphylaxis
Several...
Therapeutic Drug Monitoring: Affecting Factors
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
Therapeutic Drug Monitoring: Overview and Classification
Antihypertensive Drugs: Thiazide-Class Diuretics
Therapeutic Drug Monitoring: Drug Analysis Methods
